By Jon "DRJ" Najarian, co-founder of OptionMonster.
NEW YORK -- Shares of Ziopharm Oncology (ZIOP) gapped higher this week, and option traders are betting on larger gains ahead.
OptionMonster's tracking systems showed heavy buying in the May 7 calls, including one big block of 3,500 contracts for 70 cents. Open interest was a mere 145 contracts coming into the session, so someone obviously believes that this $245,000 investment will yield big returns.
Calls lock in the price investors must pay to buy a stock. They can generate nice leverage in the event of a rally but will expire worthless if the shares don't rise above the $7 strike price by mid-May.Ziopharm came into the week as a $4 stock. Now, after a presentation at an industry conference and Phase III trials of Palifosfamide treatment on soft-tissue sarcoma looking extremely positive, shares are closer to $5. Palifosfamide belongs to a group of chemotherapy drugs called alkylating agents, which halt tumor growth by binding to cancer-cell DNA and interfering with its function. Full results are expected by the end of this quarter. Ziopharm shares ended Wednesday's session up 0.21% to $4.70. Calls dominated its option activity, outnumbering puts by a bullish 15-to-1 ratio. Najarian owns ZIOP call spreads.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV